Research ArticleOriginal Article
Open Access

BOLA family genes are the drivers and potential biomarkers of survival in kidney renal clear cell carcinoma patients

Mohammed Alissa, Abdullah Alghamdi, Suad A. Alghamdi, Mohammed A. Alshehri, Meshari A. Alsuwat, Mamdouh Allahyani and Ali G. Alkhathami
Saudi Medical Journal November 2024, 45 (11) 1207-1218; DOI: https://doi.org/10.15537/smj.2024.45.11.20240604

References

  1. 1.↵
    1. Schuhmacher P,
    2. Kim E,
    3. Hahn F,
    4. Sekula P,
    5. Jilg CA,
    6. Leiber C, et al.
    Growth characteristics and therapeutic decision markers in von Hippel-Lindau disease patients with renal cell carcinoma. Orphanet J Rare Dis 2019; 14: 235.
    OpenUrlPubMed
  2. 2.↵
    1. Nezami BG,
    2. MacLennan GT
    . Clear cell renal cell carcinoma: a comprehensive review of its histopathology, genetics, and differential diagnosis. Int J Surg Pathol 2024: 10668969241256111.
  3. 3.↵
    1. Sharma AK,
    2. Sharma M,
    3. Sharma AK,
    4. Sharma M
    . Mapping the impact of environmental pollutants on human health and environment: a systematic review and meta-analysis. J Geochem Explor 2023: 107325.
  4. 4.↵
    1. Yoshida K,
    2. Takagi T,
    3. Kondo T,
    4. Kobayashi H,
    5. Iizuka J,
    6. Fukuda H, et al.
    Efficacy of axitinib in patients with metastatic renal cell carcinoma refractory to nivolumab therapy. Jpn J Clin Oncol 2019; 49: 576-580.
    OpenUrlPubMed
  5. 5.↵
    1. Wang D,
    2. Wang Z,
    3. Tao Y
    . Prognostic values of BolA family member expression in hepatocellular carcinoma. Biomed Res Int 2022; 2022: 8360481.
    OpenUrlPubMed
  6. 6.↵
    1. Liang M,
    2. Fei Y,
    3. Wang Y,
    4. Chen W,
    5. Liu Z,
    6. Xu D, et al.
    Integrative analysis of the role of BOLA2B in human pan-cancer. Front Genet 2023; 14: 1077126.
    OpenUrlPubMed
  7. 7.↵
    1. Yu Q,
    2. Tai YY,
    3. Tang Y,
    4. Zhao J,
    5. Negi V,
    6. Culley MK, et al.
    BOLA (BolA family member 3) deficiency controls endothelial metabolism and glycine homeostasis in pulmonary hypertension. Circulation 2019; 139: 2238-2255.
    OpenUrlPubMed
  8. 8.↵
    1. da Silva AA,
    2. Galego L,
    3. Arraiano CM
    . New perspectives on BolA: a still mysterious protein connecting morphogenesis, biofilm production, virulence, iron metabolism, and stress survival. Microorganisms 2023; 11: 632.
    OpenUrlPubMed
  9. 9.↵
    1. Zhu M,
    2. Xiao S
    . Expression profiles and prognostic values of BolA family members in ovarian cancer. J Ovarian Res 2021; 14: 75.
    OpenUrlPubMed
  10. 10.↵
    1. Gupta N
    . DNA extraction and polymerase chain reaction. J Cytol 2019; 36: 116-117.
    OpenUrlPubMed
  11. 11.↵
    1. Wang C,
    2. Hou X,
    3. Qi N,
    4. Li C,
    5. Luo Y,
    6. Hu D, et al.
    An optimized method to obtain high-quality RNA from different tissues in Lilium davidii var. unicolor. Sci Rep 2022; 12: 2825.
    OpenUrlPubMed
  12. 12.↵
    1. Tao YM,
    2. Liu Z,
    3. Liu HL
    . Dickkopf-1 (DKK1) promotes invasion and metastasis of hepatocellular carcinoma. Dig Liver Dis 2013; 45: 251-257.
    OpenUrlPubMed
  13. 13.↵
    1. Tang G,
    2. Cho M,
    3. Wang X
    . OncoDB: an interactive online database for analysis of gene expression and viral infection in cancer. Nucleic Acids Res 2022; 50: D1334-D1339.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Chandrashekar DS,
    2. Bashel B,
    3. Balasubramanya SAH,
    4. Creighton CJ,
    5. Ponce-Rodriguez I,
    6. Chakravarthi BVSK, et al.
    UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia 2017; 19: 649-658.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Lánczky A,
    2. Győrffy B
    . Web-based survival analysis tool tailored for medical research (KMplot): development and implementation. J Med Internet Res 2021; 23: e27633.
    OpenUrlPubMed
  16. 16.↵
    1. Cerami E,
    2. Gao J,
    3. Dogrusoz U,
    4. Gross BE,
    5. Sumer SO,
    6. Aksoy BA, et al.
    The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012; 2: 401-404.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Ru B,
    2. Wong CN,
    3. Tong Y,
    4. Zhong JY,
    5. Zhong SSW,
    6. Wu WC, et al.
    TISIDB: an integrated repository portal for tumor-immune system interactions. Bioinformatics 2019; 35: 4200-4202.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Sherman BT,
    2. Hao M,
    3. Qiu J,
    4. Jiao X,
    5. Baseler MW,
    6. Lane HC, et al.
    DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update). Nucleic Acids Res 2022; 50: W216-W221.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Wishart DS,
    2. Knox C,
    3. Guo AC,
    4. Cheng D,
    5. Shrivastava S,
    6. Tzur D, et al.
    DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res 2008; 36: D901-D906.
    OpenUrlCrossRefPubMedWeb of Science
  20. 20.↵
    1. Li S,
    2. Xu W
    . Mining TCGA database for screening and identification of hub genes in kidney renal clear cell carcinoma microenvironment. J Cell Biochem 2020; 121: 3952-3960.
    OpenUrlPubMed
  21. 21.↵
    1. Wang XF,
    2. Lei W,
    3. Liu CM,
    4. Yang J,
    5. Zhu YH
    . BOLA3 is a prognostic-related biomarker and correlated with immune infiltrates in lung adenocarcinoma. Int Immunopharmacol 2022; 107: 108652.
    OpenUrlPubMed
  22. 22.↵
    1. Luo J,
    2. Wang D,
    3. Zhang S,
    4. Hu K,
    5. Wu H,
    6. Li J, et al.
    BolA family member 2 enhances cell proliferation and predicts a poor prognosis in hepatocellular carcinoma with tumor hemorrhage. J Cancer 2019; 10: 4293-4304.
    OpenUrlPubMed
  23. 23.↵
    1. Zheng W,
    2. Zhang S,
    3. Guo H,
    4. Chen X,
    5. Huang Z,
    6. Jiang S, et al.
    Multi-omics analysis of tumor angiogenesis characteristics and potential epigenetic regulation mechanisms in renal clear cell carcinoma. Cell Commun Signal 2021; 19: 39.
    OpenUrlPubMed
  24. 24.
    1. Ricketts CJ,
    2. Hill VK,
    3. Linehan WM
    . Tumor-specific hypermethylation of epigenetic biomarkers, including SFRP1, predicts for poorer survival in patients from the TCGA kidney renal clear cell carcinoma (KIRC) project. PLoS One 2014; 9: e85621.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Xie L,
    2. Wu S,
    3. He R,
    4. Li S,
    5. Lai X,
    6. Wang Z
    . Identification of epigenetic dysregulation gene markers and immune landscape in kidney renal clear cell carcinoma by comprehensive genomic analysis. Front Immunol 2022; 13: 901662.
    OpenUrlPubMed
  26. 26.↵
    1. Cammarano A,
    2. Dello Iacono S,
    3. Meglio C,
    4. Nicolais L
    . Advances in transdermal drug delivery systems: a bibliometric and patent analysis. Pharmaceutics 2023; 15: 2762.
    OpenUrlPubMed
  27. 27.↵
    1. Lee H,
    2. Myoung H,
    3. Kim SM
    . Review of 2 immunosuppressants: tacrolimus and cyclosporine. J Korean Assoc Oral Maxillofac Surg 2023; 49: 311-323.
    OpenUrlCrossRefPubMed
  28. 28.
    1. Rawat G,
    2. Kolhe S,
    3. Rana D,
    4. Salave S,
    5. Benival D
    . Exploring the therapeutic potential of cyclosporine for ophthalmic indications by novel carrier systems. Crit Rev Ther Drug Carrier Syst 2023; 40: 1-45.
    OpenUrl
  29. 29.↵
    1. Pal V,
    2. Verma S
    . Patented formulations, nanotherapeutics, and herbal compound applications for dry eye: a review. Curr Drug Ther 2024; 19: 455-469.
    OpenUrl
  30. 30.↵
    1. Montenegro RC,
    2. Howarth A,
    3. Ceroni A,
    4. Fedele V,
    5. Farran B,
    6. Mesquita FP, et al.
    Identification of molecular targets for the targeted treatment of gastric cancer using dasatinib. Oncotarget 2020; 11: 535-549.
    OpenUrlCrossRefPubMed
  31. 31.
    1. da Silva TA,
    2. Gomes JHR,
    3. de Bulhões LCG,
    4. Neto RMS
    . Therapeutic potential of quercetin based on nanotechnology: a review. [Updated 2019; accessed 2024 Feb 11]. Available from: https://www.researchgate.net/publication/335668782_Therapeutic_Potential_of_Quercetin_Based_on_Nanotechnology_A_Review
  32. 32.↵
    1. Juiz PJL,
    2. Ferreira LTB,
    3. Pires EA,
    4. Villarreal CF
    . Patent mining on the use of antioxidant phytochemicals in the technological development for the prevention and treatment of periodontitis. Antioxidants (Basel) 2024; 13: 566.
    OpenUrlPubMed
  33. 33.↵
    1. Kumar P,
    2. Mangla B,
    3. Javed S,
    4. Ahsan W,
    5. Musyuni P,
    6. Ahsan A, et al.
    Gefitinib: an updated review of its role in the cancer management, its nanotechnological interventions, recent patents, and clinical trials. Recent Pat Anticancer Drug Discov 2023; 18: 448-469.
    OpenUrlPubMed
  34. 34.↵
    1. Mucke HA
    . Drug repurposing patent applications: October-December 2023. Assay Drug Dev Technol 2024; 22: 160-167.
    OpenUrl
  35. 35.↵
    1. Sahasrabudhe SA,
    2. Terluk MR,
    3. Kartha RV
    . N-acetylcysteine pharmacology and applications in rare diseases-repurposing an old antioxidant. Antioxidants (Basel) 2023; 12: 1316.
    OpenUrlPubMed
  36. 36.↵
    1. Voicu V,
    2. Brehar FM,
    3. Toader C,
    4. Covache-Busuioc RA,
    5. Corlatescu AD,
    6. Bordeianu A, et al.
    Cannabinoids in medicine: a multifaceted exploration of types, therapeutic applications, and emerging opportunities in neurodegenerative diseases and cancer therapy. Biomolecules 2023; 13: 1388.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords